

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

August 30, 2012

Commission File Number: 0-29374

EDAP TMS S.A.
Parc Activite La Poudrette Lamartine
4/6 Rue du Dauphine
69120 Vaulx-en-Velin - France

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [] Form 40-F []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

This report on Form 6-K is hereby incorporated by reference in the following registration statements of EDAP TMS S.A. on Form F-3: file number 333-136811, 333-169793, 333-177224 and 333-179689.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 30, 2012
EDAP TMS S.A.

/s/ ERIC SOYER
ERIC SOYER
CHIEF FINANCIAL OFFICER

EDAP Reports Second Quarter 2012 Revenues Up 61%

Second Quarter 2012 Highlights

- Revenues increased 61% year-over-year to EUR 6.1 million (USD 7.8 million)
- Strong lithotripsy sales with fourteen devices sold globally
- Strengthened third quarter device backlog to sixteen lithotripsy devices at the end of August 2012
- Completed U.S. FDA HIFU trial two year follow-up phase in June 2012
- On track to file PMA submission for Ablatherm-HIFU Phase II/III clinical trial in fourth quarter 2012
- Retained Greenleaf Health as strategic advisor on U.S. FDA submission

LYON, France, Aug. 30, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today financial results for the second quarter ended June 30, 2012.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "Market acceptance of our renewed lithotripsy device platform continues to grow and contributed to our strong second quarter results. Our quarterly revenues rose 61% year-over-year reflecting the sale of fourteen lithotripsy devices. Our strengthened global sales team is continuing to transform sales leads into confirmed purchase orders as our replenished device backlog now stands at sixteen lithotripsy machines."

Mr. Oczachowski continued, "The two year anniversary of the last patient treated in the ENLIGHT trial was in June 2012 and the subsequent patient follow-up visits and data collection were completed in the second half of August in line with our IDE approved clinical protocol. The EDAP teams in the U.S. and France are compiling the PMA submission file, inclusive of both clinical and manufacturing data, for a projected filing in the fourth quarter of 2012.

Recent Developments

In August, EDAP retained Greenleaf Health LLC, a full service regulatory consulting firm, to provide high-level strategic guidance regarding the final stages of its Ablatherm-HIFU (High Intensity Focused Ultrasound) ENLIGHT U.S. Phase II/III clinical trial for the indication of low risk, localized prostate cancer. Greenleaf Health joins the established EDAP team of experts, both internal and external, inclusive of specialized legal, regulatory, and Clinical Research Organization advisors.

In August, EDAP confirmed the completion of all follow-up visits in connection with its Ablatherm-HIFU ENLIGHT U.S. clinical trial for the indication of low risk, localized prostate cancer. The Company is on track to file its Premarket Approval (PMA) with the U.S. FDA in the fourth quarter of 2012.

In June, EDAP's experts in HIFU technology presented their recent advances in the development of therapeutic focused ultrasound at the 12th International Symposium of Therapeutic Ultrasound (ISTU 2012) held in Germany. Top level technical presentations from the Company's partner INSERM, a French public research laboratory, addressed the successful evaluation of HIFU technology in targeting liver cancer. Other presentations related to HIFU as a therapy for prostate cancer, and included a poster that examined data from large cohorts of prostate cancer patients treated with the Ablatherm-HIFU over more than ten years, computed from a comprehensive clinical registry. The long-term results confirm EDAP as the most advanced player in the use of HIFU to address prostate cancer.

During the second quarter, the United Kingdom's National Institute for Health and Clinical Excellence (NICE), an independent organization that advises the National Health Service (NHS) on treatment and care, published guidance regarding focal therapy using HIFU to treat localized prostate cancer. In its International Procedure Guidance 424 on focal HIFU, NICE highlighted the 'potential for focal HIFU to avoid many of the complications of more radical treatment procedures' for localized prostate cancer in properly selected patients.

During the second quarter, EDAP's Ablatherm-HIFU was successfully utilized by leading urology surgeons at the St-Augustin Urology Clinic in Bordeaux, France to eradicate prostate cancer tumors via a focal approach. This highly regarded urology practice is now positioning the focal therapy procedure using EDAP's device as a 'must have complement' to robotic surgery.

In May, EDAP showcased its Ablatherm-HIFU and its Sonolith i-move at the American Urological Association (AUA) 2012 Annual Meeting. Prostate cancer data generated using Ablatherm-HIFU was featured in two scientific sessions at AUA and in three poster presentations at the 27th Annual Meeting of the Engineering and Urology Society that was held concurrently with the AUA. EDAP experienced record attendance from U.S. urologists at its AUA booth.

Second Quarter 2012 Results

Total revenue for the second quarter 2012 was EUR 6.1 million (USD 7.8 million), up 61% as compared to EUR 3.8 million (USD 5.5 million) for the second quarter 2011.

Total revenue for the lithotripsy division was EUR 5.0 million (USD 6.4 million) for the three months ended June 30, 2012, up 112% as compared to EUR 2.4 million (USD 3.4 million) for the year ago period. During the second quarter 2012, the Company recorded sales of fourteen lithotripsy machines, comprised of six Sonolith i-move devices, four Sonolith i-sys devices and four Sonolith Praktis devices, compared to a total of three devices sold in the second quarter of 2011.

Total revenue for the HIFU division was EUR 1.1 million (USD 1.4 million) for the second quarter 2012, compared to EUR 1.4 million (USD 2.1 million) for the same period last year. The Company did not record any Ablatherm-HIFU machine sale in the second quarter 2012, while, results for the second quarter 2011 reflected the sale of one Ablatherm machine.

Gross profit for the second quarter 2012 was EUR 2.4 million (USD 3.1 million), compared to EUR 1.5 million (USD 2.2 million) for the year ago period. Gross profit margin was 39.1% in the second quarter 2012, compared to 40.2% in the year ago period. The change in the gross profit margin was attributed to the evolution in product mix.

Operating expenses were EUR 3.3 million (USD 4.2 million) for the second quarter 2012, compared to EUR 2.8 million (USD 4.1 million) for the same period in 2011. Operating loss was EUR 937,000 (USD 1.2 million) for the second quarter 2012, compared to EUR 1.3 million (USD 1.8 million) in the second quarter of 2011.

First Six Months 2012 Results

Total revenue for the first half of 2012 was EUR 11.0 million (USD 14.3 million), up 27% as compared to EUR 8.6 million (USD 12.3 million) for the first half of 2011.

Gross profit for the first half of 2012 was EUR 4.3 million (USD 5.6 million), up 23% from EUR 3.5 million (USD 5.0 million) for the first half of 2011. Gross profit margin was 39.2% in the first half of 2012, compared to 40.5% in the first half of 2011.

Operating loss for the first half of 2012 was stable at EUR 1.9 million (USD 2.5 million) and net loss for the first half of 2012 was EUR 5.6 million (USD 7.2 million), or EUR 0.30 per diluted share, as compared to net income of EUR 1.2 million (USD 1.8 million), or EUR 0.13 per diluted share, in the first half of 2011. Net loss in 2012 included a non-cash interest expense of EUR 3.3 million (USD 4.2 million) to reflect the accounting fair value impact of the January 2012 exchange offering on its convertible debentures and related warrants.

At June 30, 2012, cash and cash equivalents, including short-term treasury investments, were EUR 8.1 million (USD 10.2 million) and reflected the payment in the second quarter 2012 of USD 2.0 million to the debt holders following the \$5.625 million registered direct placement in March 2012.

Conference Call

EDAP will hold a conference call today, Thursday, August 30, 2012, at 8:30 a.m. EDT to discuss the results. The dial-in numbers are 1-877-317-6789 for domestic callers and 1-412-317-6789 for international. The conference ID number for both is 10016762. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.edap-tms.com.

After the live webcast, the call will remain available on EDAP's website, www.edap-tms.com, through September 30, 2012. In addition, a telephonic replay of the call will be available until September 11, 2012. The replay dial-in numbers are 1-877-344-7529 for domestic callers and 1-412-317-0088 for international callers. Please use event passcode 10016762.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm(R), the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith(R) range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com>, and <http://www.hifu-planet.com>.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements.. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others the uncertainties of the U.S. FDA approval process, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device,.. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(Amounts in thousands of Euros and U.S. Dollars, except per share data)

	Three Months Ended :		Three Months Ended :	
	June 30, 2012 Euros	June 30, 2011 Euros	June 30, 2012 \$US	June 30, 2011 \$US
Sales of goods	3,747	1,312	4,779	1,912
Net Sales of RPP and Leases	1,088	1,160	1,388	1,691
Sales of spare parts and Services	1,290	1,316	1,646	1,917
TOTAL NET SALES	6,126	3,788	7,813	5,520
Other revenues	--	3	--	4
TOTAL REVENUES	6,126	3,791	7,813	5,524
Cost of goods	(2,200)	(806)	(2,806)	(1,175)
Cost of RPP and Leases	(608)	(577)	(775)	(841)
Cost of spare parts & services	(925)	(884)	(1,179)	(1,288)
Cost of sales	(3,732)	(2,267)	(4,760)	(3,304)
GROSS PROFIT	2,394	1,524	3,053	2,220
Research & development expenses	(854)	(646)	(1,090)	(941)
Marketing & Sales expenses	(1,536)	(1,423)	(1,959)	(2,074)
G & A expenses	(940)	(715)	(1,199)	(1,041)
Total operating expenses	(3,331)	(2,784)	(4,248)	(4,056)
OPERATING PROFIT (LOSS)	(937)	(1,260)	(1,195)	(1,836)
Interest (expense) income, net	(2,109)	(173)	(2,690)	(253)
Currency exchange gains (loss), net	296	39	377	57
Other income (loss), net	33	(2)	42	(2)
INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST	(2,717)	(1,396)	(3,465)	(2,034)
Income tax (expense) credit	49	(47)	62	(69)
NET INCOME (LOSS)	(2,669)	(1,443)	(3,403)	(2,103)
Earning per share – Basic	(0.15)	(0.11)	(0.19)	(0.16)
Average number of shares used in computation of EPS	18,257,273	13,148,421	18,257,273	13,148,421
Earning per share – Diluted	(0.15)	(0.11)	(0.19)	(0.16)
Average number of shares used in computation of EPS for positive net income	18,249,273	13,465,858	18,249,273	13,465,858

NOTE: Translated for convenience of the reader to U.S. dollars at the 2012 average three months noon buying rate of 1 Euro = 1.2753 USD, and 2011 average three months noon buying rate of 1 Euro = 1.4573 USD.

EDAP TMS S.A.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(Amounts in thousands of Euros and U.S. Dollars, except per share data)

	Six Months Ended :		Six Months Ended :	
	June 30, 2012 Euros	June 30, 2011 Euros	June 30, 2012 \$US	June 30, 2011 \$US
Sales of goods	6,212	3,736	8,076	5,318
Net Sales of RPP and Leases	2,201	2,352	2,862	3,348
Sales of spare parts and Services	2,550	2,537	3,316	3,612
TOTAL NET SALES	10,963	8,625	14,253	12,278
Other revenues	--	25	--	36
TOTAL REVENUES	10,963	8,650	14,253	12,313
Cost of goods	(3,575)	(2,259)	(4,648)	(3,215)
Cost of RPP and Leases	(1,243)	(1,210)	(1,615)	(1,723)

Cost of spare parts & services	(1,850)	(1,681)	(2,404)	(2,394)
Cost of sales	(6,667)	(5,151)	(8,668)	(7,332)
GROSS PROFIT	4,296	3,500	5,585	4,982
Research & development expenses	(1,563)	(1,182)	(2,032)	(1,683)
Marketing & Sales expenses	(2,959)	(2,763)	(3,846)	(3,933)
G & A expenses	(1,718)	(1,485)	(2,233)	(2,113)
Total operating expenses	(6,239)	(5,430)	(8,111)	(7,729)
OPERATING PROFIT (LOSS)	(1,943)	(1,930)	(2,526)	(2,748)
Interest (expense) income, net	(3,665)	1,194	(4,764)	1,700
Currency exchange gains (loss), net	28	(400)	36	(570)
Other income (loss), net	40	--	51	--
INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST	(5,540)	(1,136)	(7,203)	(1,618)
Income tax (expense) credit	(25)	(94)	(33)	(134)
NET INCOME (LOSS)	(5,565)	(1,230)	(7,236)	(1,751)
Earning per share – Basic	(0.30)	(0.09)	(0.40)	(0.13)
Average number of shares used in computation of EPS	18,257,273	13,148,421	18,257,273	13,148,421
Earning per share – Diluted	(0.30)	(0.09)	(0.40)	(0.13)
Average number of shares used in computation of EPS for positive net income	18,277,698	13,591,364	18,277,698	13,591,364

NOTE: Translated for convenience of the reader to U.S. dollars at the 2012 average six months noon buying rate of 1 Euro = 1.3001 USD, and 2011 average six months noon buying rate of 1 Euro = 1.4235 USD.

EDAP TMS S.A.
CONSOLIDATED BALANCE SHEETS HIGHLIGHTS (UNAUDITED)
(Amounts in thousands of Euros and U.S. Dollars)

	June 30, 2012 Euros	March 31, 2012 Euros	June 30, 2012 \$US	March 31, 2012 \$US
Cash, cash equivalents and short term investments	8,068	10,714	10,221	14,311
Total current assets	25,834	26,754	32,726	35,734
Total current liabilities	13,075	13,744	16,563	18,357
Shareholders' Equity	11,682	13,618	14,799	18,189

NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.2668 USD, on June 30, 2012 and at the noon buying rate of 1 Euro = 1.3356 USD, on March 31, 2012.

EDAP TMS S.A.
CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
SIX MONTHS ENDED JUNE 30, 2012
(Amounts in thousands of Euros)

	HIFU Division	UDS Division	FDA Trials	Corporate	Total After Consolidation
Sales of goods	466	5,746			6,212
Sales of RPPs & Leases	1,505	696			2,201
Sales of spare parts & services	454	2,096			2,550
TOTAL NET SALES	2,426	8,538			10,963
Other revenues	(3)	3			--
TOTAL REVENUES	2,422	8,541			10,963

GROSS PROFIT	1,103 45.5%	3,193 37.4%		4,296 39.2%
Research & Development	(717)	(451)	(395)	(1,563)
Total SG&A plus depreciation	<u>(1,349)</u>	<u>(2,697)</u>	<u>(42)</u>	<u>(589)</u>
OPERATING PROFIT (LOSS)	(964)	46	(437)	(589)
				(1,943)

CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com

Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com